Cannabis and Mental Health: Why ‘Cannabis’ and ‘d9-THC’ Are Not the Same Thing
When headlines report that 'cannabis' is detrimental for any number of things, the term is almost exclusively used as a proxy for d9-THC.
Cannabis and Mental Health: It’s Not Just About ‘Cannabis’
It is likely more appropriate to view cannabis use as a contributing factor to a condition with a multifactorial etiology (e.g., genetic predisposition, use of other drugs, familial and social factors), or the result of individuals having a shared…
Medical Cannabis Evidence Map: Broad Promise, Variable Proof
When considering only high-quality systematic reviews, as evaluated by the AMSTAR 2 tool, 42 out of 67 descriptions of treatment effects for up to 20 health outcomes were classified as 'Positive' or 'Potentially Positive.' These outcomes included pain,…
Unveiling Neurological Benefits: A Review of Hemp Leaf, Flower, Seed Oil Extract, and Their Phytochemical Properties in Neurological Disorders.
Neurological disorders such as epilepsy, Alzheimer's disease, Parkinson's disease, and multiple sclerosis present significant global health care challenges, ...
Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.
To assess the efficacy of cannabis for the treatment of acute migraine. Preclinical and retrospective studies suggest cannabinoids may be effective in migrai...
Cannabinoids in Pediatric Care: Clinical Evidence Review
Clinical Takeaway Current evidence on cannabinoids in pediatric medicine spans 276 studies across multiple designs, with the strongest data coming from interventional and observational research on plant-derived and pharmaceutical cannabinoid treatments.…
`Cannabinoid Clinical Trials: CBD and WADA Drug Testing`
Clinical Takeaway Daily use of a broad-spectrum CBD supplement containing trace amounts of other cannabinoids can result in urine concentrations of WADA-prohibited substances such as CBG and CBDV, potentially placing athletes at risk for a positive…
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class…
Boulder and CBD: The Entourage Effect Explained
If you use CBD products, understanding the entourage effect helps explain why full-spectrum formulations may offer greater therapeutic benefit than isolated CBD alone. An overview of the entourage effect explains how CBD works synergistically with other…
United States Drug Enforcement Administration Cannabis-Related Documents
Understanding how the DEA classifies cannabis compounds is essential for patients and providers navigating the increasingly complex legal landscape between hemp, CBD, and controlled substances. The DEA has published an updated collection of…